Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo

Blood (2021) 138 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2021-151042

Published: 2021

Journal Articles

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

Fieke W. Hoff, Anneke D. van Dijk, Yihua Qiu, Peter P. Ruvolo, Robert B. Gerbing, Amanda R. Leonti, Gaye N. Jenkins, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Eveline S. J. M. de Bont, Sophia W. M. Bruggeman, Steven M. Kornblau, Terzah M. Horton

Blood (2021) 137 (8): 1050–1060.

https://doi.org/10.1182/blood.2020005208

Published: 2021

Includes: Supplemental data

Journal Articles

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Muharrem Muftuoglu, MD, Po Yee Mak, Vivian Ruvolo, MS, Yuki Nishida, MDPhD, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143371

Published: 2020

Journal Articles

p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development

Rasoul Pourebrahimabadi, MD PhD, Zoe Alaniz, Lauren B Ostermann, Hung Alex Luong, Rafael Heinz Montoya, Peter P. Ruvolo, PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 523.

https://doi.org/10.1182/blood-2019-127245

Published: 2019

Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD

Blood (2019) 134 (Supplement_1): 2550.

https://doi.org/10.1182/blood-2019-128626

Published: 2019

Journal Articles

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Anneke D. van Dijk, BS, Peter P. Ruvolo, PhD, Fieke W Hoff, BSc, Yihua Qiu, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Anders E. Kolb, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, Eveline S. de Bont, MD PhD, Sophia W.M. Bruggeman, PhD, Terzah M Horton, MD PhD, Steven M. Kornblau, MD

Blood (2019) 134 (Supplement_1): 2676.

https://doi.org/10.1182/blood-2019-128579

Published: 2019

Journal Articles

Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns

Muharrem Muftuoglu, MD, Vivian Ruvolo, Yuki Nishida, MD PhD, Po Yee Mak, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 882.

https://doi.org/10.1182/blood-2019-131784

Published: 2019

Journal Articles

Genetic Dissection of p53 Driven Senescence of Bone Marrow Mesenchymal Cells in Acute Myeloid Leukemia

Rasoul Pourebrahim, MD PhD, Peter P. Ruvolo, PhD, Steven M. Kornblau, MD, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2018-99-117585

Published: 2018

Journal Articles

AXL Expression in Pediatric AML Is Associated with Putative LSC and Correlates with a Distinct Set of Proteins Associated with Cell Metabolism, Cell Cycle, and Unfolded Protein Response

Fieke W Hoff, BSc, Peter P. Ruvolo, PhD, Yihua Qiu, Michael Andreeff, MD PhD, Eveline S. de Bont, MD, Terzah M. Horton, MD PhD, Steven M. Kornblau, MD

Blood (2018) 132 (Supplement 1): 2686.

https://doi.org/10.1182/blood-2018-99-112555

Published: 2018

Journal Articles

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Peter P. Ruvolo, PhD, Huaxian Ma, MS, Vivian Ruvolo, MS, Xiaorui Zhang, BS, Hong Mu, MD PhD, Tomoko Yasuhiro, Kohei Tanaka, Toshio Yoshizawa, PhD, Weiguo Zhang, MD PhD, Jorge E. Cortes, MD, Michael Andreeff, MD PhD, Sean M Post, PhD

Blood (2018) 132 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2018-99-112211

Published: 2018

Journal Articles

Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization

Akihide Yoshimi, MD, Zhaoqi Liu, PhD, Wang Jiguang, Hana Cho, MSc, Stanley C Lee, PhD, Michelle Ki, BSc, Lillian E Bitner, BSc, Timothy Chu, Anthony R Mato, MD, Peter P. Ruvolo, PhD, Giulia Fabbri, Laura Pasqualucci, MD, Raul Rabadan, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 882.

https://doi.org/10.1182/blood-2018-99-110328

Published: 2018

Journal Articles

The TGF-β/SMAD Signaling Pathway As a Mediator of NK Cell Dysfunction and Immune Evasion in Myelodysplastic Syndrome

Blood (2017) 130 (Supplement 1): 53.

https://doi.org/10.1182/blood.V130.Suppl_1.53.53

Published: 2017

Journal Articles

Up-Regulation of iNOS in AML Blasts Creates an Immunosuppressive Microenvironment, Inhibits T-Cell Proliferation and Transforms T-Cells Towards a Tumor-Tolerating Phenotype

Rodrigo Jacamo, PhD, Nguyet-Minh Hoang, B.A., Ahmed Al Rawi, Charlie Ly, BS, Robin Parihar, MDPhD, Teresa McQueen, MS, Peter P. Ruvolo, PhD, Patrick Williams, MD PhD, Gheath Alatrash, DO, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2443.

https://doi.org/10.1182/blood.V130.Suppl_1.2443.2443

Published: 2017

Journal Articles

Robust Bioinformatics Approach for Identifying Novel AML LSC Targets: Putative Role of Galectin-1 in the Immune-Microenvironment

Shelley Herbrich, MS, Peter P. Ruvolo, PhD, Vivian Ruvolo, PhD, Keith Baggerly, PhD, Gheath Alatrash, DO, PhD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 3962.

https://doi.org/10.1182/blood.V130.Suppl_1.3962.3962

Published: 2017

Journal Articles

Galectin 3 Protein Network Analysis By Reverse Protein Arrays Demonstrates Regulation of MCL-1, PKC Delta and CD74 Associated with Poor Survival in Patients with AML

Peter P. Ruvolo, PhD, Chenyue Hu, Yihua Qiu, Vivian Ruvolo, PhD, Kevin R Coombes, Amina Qutub, Michael Andreeff, MD PhD, Steven Kornblau, MD

Blood (2017) 130 (Supplement 1): 1395.

https://doi.org/10.1182/blood.V130.Suppl_1.1395.1395

Published: 2017

Journal Articles

Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia

Sujan Piya, Steven M. Kornblau, Vivian R. Ruvolo, Hong Mu, Peter P. Ruvolo, Teresa McQueen, R. Eric Davis, Numsen Hail, Jr, Hagop Kantarjian, Michael Andreeff, Gautam Borthakur

Blood (2016) 128 (9): 1260–1269.

https://doi.org/10.1182/blood-2016-01-692244

Published: 2016

Includes: Supplemental data

Journal Articles

The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide

Blood (2015) 126 (23): 1709.

https://doi.org/10.1182/blood.V126.23.1709.1709

Published: 2015

Journal Articles

Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

Rongqing Pan, Vivian R. Ruvolo, Jun Wei, Marina Konopleva, John C. Reed, Maurizio Pellecchia, Michael Andreeff, Peter P. Ruvolo

Blood (2015) 126 (3): 363–372.

https://doi.org/10.1182/blood-2014-10-604975

Published: 2015

Includes: Supplemental data

Journal Articles

Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling

Peter P. Ruvolo, PhD, Venkata Lokesh Battula, PhD, YiHua Qui, MD, Vivian R Ruvolo, MA, Rodrigo Jacamo, PhD, Zhihong Zeng, MD, Rui-Yu Wang, MD PhD, Teresa McQueen, BS, Arvind Rao, SukYoung Yoo, Phuong M Le, Numsen Hail, PhD, Bing Z Carter, PhD, Steven M. Kornblau, MD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 4376.

https://doi.org/10.1182/blood.V124.21.4376.4376

Published: 2014

Journal Articles

Acute Myeloid Leukemia Cells Acquire Chemo-Resistance By Inducing Osteoblast Differentiation in Mesenchymal Stem Cells through up-Regulation of RUNX2

Venkata Lokesh Battula, PhD, Phuong M Le, Jeffrey Sun, BS, Teresa McQueen, BS, Anitha Somanchi, MS, Rui-Yu Wang, MD PhD, Dirk Strunk, MD, Elizabeth J Shpall, MD, Peter P. Ruvolo, PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 2929.

https://doi.org/10.1182/blood.V124.21.2929.2929

Published: 2014

NARROW

Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns

Genetic Dissection of p53 Driven Senescence of Bone Marrow Mesenchymal Cells in Acute Myeloid Leukemia

AXL Expression in Pediatric AML Is Associated with Putative LSC and Correlates with a Distinct Set of Proteins Associated with Cell Metabolism, Cell Cycle, and Unfolded Protein Response

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization

The TGF-β/SMAD Signaling Pathway As a Mediator of NK Cell Dysfunction and Immune Evasion in Myelodysplastic Syndrome

Up-Regulation of iNOS in AML Blasts Creates an Immunosuppressive Microenvironment, Inhibits T-Cell Proliferation and Transforms T-Cells Towards a Tumor-Tolerating Phenotype

Robust Bioinformatics Approach for Identifying Novel AML LSC Targets: Putative Role of Galectin-1 in the Immune-Microenvironment

Galectin 3 Protein Network Analysis By Reverse Protein Arrays Demonstrates Regulation of MCL-1, PKC Delta and CD74 Associated with Poor Survival in Patients with AML

Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia

The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide

Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling

Acute Myeloid Leukemia Cells Acquire Chemo-Resistance By Inducing Osteoblast Differentiation in Mesenchymal Stem Cells through up-Regulation of RUNX2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only